We advised the underwriters on the investment-grade debt offering

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by Illumina, Inc. of $500 million aggregate principal amount of 0.550% notes due 2023 and $500 million aggregate principal amount of 2.550% notes due 2031.

Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis. The company’s products and services serve customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings.

The Davis Polk capital markets team included partner Alan F. Denenberg, counsel Jeffrey Gould and associate Dana Lueck-Mammen. Partner Lucy W. Farr and associate Ben Levenback provided tax advice. Associate Jay Frankel provided intellectual property advice. Associate Leon E. Salkin provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.